Tra‐1‐60: A new serum marker in patients with germ‐cell tumors

J. Marrink, P. W. Andrews, P. J. Van Brummen, H. J. De Jong, D. T.H. Sleijfer, H. Schraffordt Koops, J. W. Oosterhuis

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

16 Citaten (Scopus)


TRA‐1‐60 is a monoclonal antibody (MAb) that recognizes a mucin‐like antigenic determinant expressed on the surface of embryonal carcinoma (EC) progenitor cells. In order to determine whether this antigen is released into the serum of patients with a non‐seminomatous germ‐cell tumor (NSGCT), we developed a sensitive 2‐step immunoenzymometric assay. Of 42 EC‐positive NSGCT patients tested, 32 (76%) were found to release TRA‐1‐60‐reactive antigen into their serum, in contrast to 1 positive finding in 10 EC‐negative NSGCT patients. The marker was found in 67% (10/15) of the EC‐positive patients who were negative for both AFP and HCG. Sera from seminoma patients did not contain elevated levels of the TRA‐1‐60 antigen. Therefore, we propose that the TRA‐1‐60 antigen is a useful additional serum marker for following the progress of NSGCT(EC+) patients.

Originele taal-2Engels
Pagina's (van-tot)368-372
Aantal pagina's5
TijdschriftInternational Journal of Cancer
Nummer van het tijdschrift3
StatusGepubliceerd - 30 sep. 1991
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Tra‐1‐60: A new serum marker in patients with germ‐cell tumors'. Samen vormen ze een unieke vingerafdruk.

Citeer dit